Sigachi Industries Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mdtw2h8yrjrmq1okuzszssm3.pdf

Key Takeaways


Revenue Growth & Market Share Strategy

Amit Raj Sinha: "Till the time they do not experience you, they do not value you. The moment they experience you, they value your products, they use your products, then they cannot let you go. This is what is bringing forward a value proposition with respect to your competition."

Margin Analysis: The Gross Margin Reset

Amit Raj Sinha: "I think in the short term, we will work to see that we are sustaining the margins. In the long term, we are working to see that we ramp it better because API's turnaround and improvement in the EBITDA is going to take time because the CEP approvals take at least 3 quarters."

API Segment: The Turnaround Bet

Amit Raj Sinha: "Once the CEP approval comes in, most chunk of our regulated customers would immediately go in for sampling and stability of the formulation. And once the stability is done, maybe meanwhile they would come for a customer comfort audit and subsequently start trials."

International Expansion & New Facilities

Amit Raj Sinha: "We are just trying to work out and have a fair mix of opportunities which remain sustainable and are risk balanced. So, on account of that, we have let go certain opportunities and we did not really look at them because we did not feel that we were in a position to be able to execute those orders, standards, products in line with those stipulated norms."

Guidance & Commitments

CommitmentSpecificsTimeline
FY25 revenue growthMarginally better than 25-30%, probably touching 30% top-line growthFY25 full year
FY25 EBITDA marginAround 21%-22%FY25 full year
Gross margin trajectoryMargins to move upward from Q3; no further decline expectedQ3 FY25 onwards
Debt-free statusCompany will be debt freeEnd of FY25
First CEP approvalPropafenone Hydrochloride CEP completionBy March 2025
API capacity utilization95%-100% of capacity utilizedBy mid-FY26
CEP approvals countAt least 6-7 CEP approvals in placeBy mid-FY26
API EBIT margins20% EBIT margins on CEP-approved productsOnce CEP approvals in place
CCS facility commercialization1,800 MTPA CCS facility in DahejBy FY26
API capacity expansionAdditional 150 KL expansion; full operationsCommencing Jan 2025; full ops by Jan 2026
Nutraceuticals trial ordersReasonable quantity of trial orders from nutraceuticals customersBy Jan or Feb 2025
Sigachi Arabia revenueRevenue from Middle East JVNext financial year (FY26)
PLI income continuityPLI incentives to continueTill FY28

Key Metrics

MetricQ2 FY25
Operating income₹124.9 cr, up 25.91% YoY
EBITDA₹29 cr, up 36.91% YoY
EBITDA margin21.38%
Gross margin47%, compared to 57% in Q1 FY25 and 53% in Q2 FY24
Revenue growth guidance (FY25)~30% top-line growth
Revenue growth guidance (annual)Not less than 25% to 30% every year
EBITDA margin guidance21%–22%
MCC capacity utilization50% (8,153 units), up 20% vs corresponding previous year
MCC realization₹212 per kg
O&M revenue growth (H1 FY25)~19.8% YoY
API revenue share (H1 FY25)8% of overall revenue, up from 4% in H1 FY24
API revenue target20%–25% of overall revenue in next 2–3 years
API capacity utilization target95%–100% by mid-FY26
Employee benefit expenses~18% of top line, up from ~14% last year
Promoter shareholding (post preferential issue)46%–48%